Format

Send to

Choose Destination
Hepatol Int. 2016 Nov;10(6):861-870. Epub 2016 Jun 21.

Hepatitis C genotype 3 disease.

Author information

1
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA. skattakuzhy@ihv.umaryland.edu.
2
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
3
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, 5415 W, Cedar Lane Suite 203b, Bethesda, MD, 20814, USA.

Abstract

Hepatitis C genotype 3 (GT-3) infection comprises up to 30 % of all HCV infections worldwide, with roughly 54.3 million cases concentrated in South and Southeast Asia. Longitudinal studies have demonstrated significantly increased rates of steatosis, fibrosis, and hepatocellular carcinoma in GT-3 disease, thus distinguishing this genotype as both the most difficult and urgent to treat. However, novel direct-acting antiviral agents currently approved have not demonstrated the uniform potency seen in GT-1 disease for GT-3. This review outlines (1) the epidemiology and natural history, (2) phase II and III clinical trials demonstrating effective treatment options, and (3) current and future therapeutic issues in the quest to eradicate hepatitis C genotype 3 disease.

KEYWORDS:

Genotype-3; Hepatitis C; Treatment review

PMID:
27328848
DOI:
10.1007/s12072-016-9748-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center